Mirum, Incyte FDA Approval of Atebrioz™ (zilurgisertib) for Fibrodysplasia

 -Once-daily oral ALK2 inhibitor approved to reduce the volume of total new heterotopic ossification in patients aged 12 years and older with FOP

-Atebrioz expected to be available in the United States in October through Mirum Access Plus (MAP), with eligible patients paying as little as $0 per month

-PROGRESS pediatric development program continues to evaluate zilurgisertib in children aged 2 to <12 years

https://www.businesswire.com/news/home/20260925436454/en/Mirum-Pharmaceuticals-and-Incyte-Announce-U.S.-FDA-Approval-of-Atebrioz-zilurgisertib-for-Adult-and-Pediatric-Patients-with-Fibrodysplasia-Ossificans-Progressiva